Gracell Biotechnologies Performance
| GRCLDelisted Stock | USD 4.02 0.26 6.07% |
The company retains a Market Volatility (i.e., Beta) of 2.28, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Gracell Biotechnologies will likely underperform. Gracell Biotechnologies right now retains a risk of 0.0%. Please check out Gracell Biotechnologies value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to decide if Gracell Biotechnologies will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Gracell Biotechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Gracell Biotechnologies is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 1.5 B |
Gracell |
Gracell Biotechnologies Relative Risk vs. Return Landscape
If you would invest 402.00 in Gracell Biotechnologies on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Gracell Biotechnologies or generate 0.0% return on investment over 90 days. Gracell Biotechnologies is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Gracell, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gracell Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gracell Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gracell Biotechnologies, and traders can use it to determine the average amount a Gracell Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GRCL |
Based on monthly moving average Gracell Biotechnologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gracell Biotechnologies by adding Gracell Biotechnologies to a well-diversified portfolio.
Gracell Biotechnologies Fundamentals Growth
Gracell Stock prices reflect investors' perceptions of the future prospects and financial health of Gracell Biotechnologies, and Gracell Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gracell Stock performance.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 96.57 M | |||
| Price To Book | 4.39 X | |||
| Price To Sales | 732.21 X | |||
| EBITDA | (509.64 M) | |||
| Cash And Equivalents | 1.71 B | |||
| Cash Per Share | 25.28 X | |||
| Total Debt | 182.98 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 16.90 X | |||
| Cash Flow From Operations | (482.65 M) | |||
| Earnings Per Share | (0.97) X | |||
| Total Asset | 1.66 B | |||
| Retained Earnings | (1.63 B) | |||
About Gracell Biotechnologies Performance
By examining Gracell Biotechnologies' fundamental ratios, stakeholders can obtain critical insights into Gracell Biotechnologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Gracell Biotechnologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the Peoples Republic of China. The company was founded in 2017 and is headquartered in Suzhou, China. Gracell Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 348 people.Things to note about Gracell Biotechnologies performance evaluation
Checking the ongoing alerts about Gracell Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gracell Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gracell Biotechnologies is not yet fully synchronised with the market data | |
| Gracell Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (496.98 M) with profit before overhead, payroll, taxes, and interest of 366 K. | |
| Gracell Biotechnologies currently holds about 1.71 B in cash with (482.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference |
- Analyzing Gracell Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gracell Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Gracell Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gracell Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gracell Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gracell Biotechnologies' stock. These opinions can provide insight into Gracell Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |